New and experimental therapeutic roles for naloxone and related opioid antagonists.
Naloxone and related opioid antagonists have been shown to have therapeutic utility in a variety of conditions. The effects of opioid antagonists in either physiological or pathological processes are most clearly seen when there is excessive occupancy of opioid receptors, as in opiate overdose. Opioid antagonists are also able to reverse several types of cardiovascular shock, conditions in which endogenous opioids appear to be mobilised, resulting in increased opioid receptor occupation. There are also more controversial circumstances in which excessive occupation of opioid receptors may assume pathological significance, such as hypercapnia. Opioid antagonists could be useful in such a situation by re-sensitising the respiratory centres to carbon dioxide. There is some evidence that opioid antagonists may benefit some schizophrenic and manic-depressive patients, suggesting that an endogenous opioid ligand might cause disturbances in mental functioning. The diversity and complexity of opioid mechanisms in the central nervous system suggest that more specific opioid antagonists could be more selective in altering physiological or pathological functioning.
D000427:Alcohol Deterrents; D000818:Animals; D001714:Bipolar Disorder / Q000188:drug therapy; D001794:Blood Pressure / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy; D002986:Clinical Trials as Topic; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D009270:Naloxone / Q000627:therapeutic use*; D009271:Naltrexone / Q000627:therapeutic use; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D012119:Respiration / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy; D012769:Shock / Q000188:drug therapy; D013124:Spinal Injuries / Q000188:drug therapy
D000427:Alcohol Deterrents; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D009270:Naloxone; D009271:Naltrexone